4basebio Plc - 4basebio annonce la fourniture de ses produits ADN opDNA™ au programme de vaccins d'un client pharmaceutique de niveau 1
4basebio Plc - 4basebio annonce la fourniture de ses produits ADN opDNA™ au programme de vaccins d'un client pharmaceutique de niveau 1
PR Newswire
LONDRES, Royaume-Uni, 10 avril
10 Avril 2024
4basebio PLC
("4basebio" ou la "Société")
4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client’s vaccine program
Cambridge, Royaume-Uni, 10 Avril 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, today announces the supply of its HQ synthetic DNA to a Tier 1 Pharma Company. Following successful completion of an opDNA™ evaluation study, our client has now progressed to HQ opDNA™ for late preclinical studies for an mRNA vaccine program. Supply of GMP grade material for clinical trials is anticipated in Q3.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.
Dr Heikki Lanckriet, CEO at the Company, commented: "This is a major achievement for our company and is significant both in terms of product quantity and value. It’s a clear recognition of the strengths of our synthetic DNA products, our product quality, and our manufacturing capabilities.
“There is strong interest in our synthetic DNA products, and we are now supporting a growing number of projects into the clinic. We expect client acquisition and revenue generation to continue accelerating as our expanding client base progress their clinical programs.”
Pour plus d'informations, veuillez contacter:
4basebio PLC Heikki Lanckriet | + 44 (0) 12 2396 7943 |
Conseiller désigné Conseillers financiers Cairn LLP Jo Tuner / Sandy Jamieson | + 44 (0) 20 7213 0880 |
Broker Marchés des capitaux Cavendish Limitée Geoff Nash/Charlie Beeson/Nigel Birks | + 44 (0) 20 7220 0500 |
Communications Lionsgate (demandes des médias) Jonathan Charles | +44 (0)77 91892509 |
Notes aux rédacteurs
À propos de 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. The company is offering GMP compliant DNA starting materials suitable for use in AAV viral vector production as well as mRNA vaccine and therapeutics production.
Énoncés prospectifs
Cette annonce peut contenir certaines déclarations sur les perspectives futures de 4basebio. Bien que les administrateurs estiment que leurs attentes reposent sur des hypothèses raisonnables, toute déclaration concernant les perspectives futures peut être influencée par des facteurs qui pourraient faire en sorte que les résultats réels soient sensiblement différents.